CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

Trial Details

NCT ID
NCT06559189
Phase
PHASE1
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CD19x22 CAR T
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Subjects must have a history of B precursor ALL with any of the following conditions:
  • Relapsed two or more times.
  • Relapsed at any time after allogeneic bone marrow transplant (BMT).
  • Relapse or refractory after single antigen targeting CAR T cell therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →